CHRONIC BETA-BLOCKER TREATMENT IN HEART FAILURE

心力衰竭的慢性 β 受体阻滞剂治疗

• 批准号: 7376447
• 负责人: E MICHAEL GILBERT
• 金额: $ 6.34万
• 依托单位: UNIVERSITY OF UTAH
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-04-01 至 2007-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7376447
• 关键词: antihypertensive agents; beta antiadrenergic agent; blood pressure; heart failure; hemodynamics; reduction

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Chronic beta-blocker treatment in heart failure is associated with increases in systolic function, improvement in hemodynamics, reversal of pathologic remodeling , improvement of symptoms, a reduction in hospitalization and a reduction in mortality. Chronic beta-blocker treatment in heart failure is associated with increases in systolic function, improvement in hemodynamics, reversal of pathologic remodeling, improvement of symptoms, a reduction in hospitalization and a reduction in mortality. The clinical evidence for the long-term benefit of beta-blocker therapy is so strong that it is now recommended therapy in all patients with class II or III heart failure symptoms who do not have specific contraindications. This study will investigate whether tolerance to the alpha 1-adrenoceptor blocking effects of carvedilol develops with chronic carvedilol therapy. We will measure the blood pressure and heart rate response to phenylephrine (a pure alpha 1-agonist) infusions in 17 subjects with heart failure. These measurements will be made prior to the initiation of carvedilol therapy, during the uptitration of carvedilol, and after 6 months of continuous carvedilol therapy. The dose of phenylephrine required to increase systolic blood pressure by 20 mm Hg (PS20) and the dose of phenylephrine required to increase diastolic blood pressure by 20 mm Hg (PD20) will be measured. Dose ratios at these doses will be calculated and compared. Prior to enrollment, a blood sample will be obtained to analyze alpha 1-adrenoceptor polymorphisms that could affect the individual's response to phenylephrine.

该子项目是利用 NIH/NCRR 资助的中心拨款提供的资源的众多研究子项目之一。子项目和研究者 (PI) 可能已从另一个 NIH 来源获得主要资金，因此可以在其他 CRISP 条目中得到体现。列出的机构是中心的机构，不一定是研究者的机构。心力衰竭的慢性β受体阻滞剂治疗与收缩功能的增强、血流动力学的改善、病理重塑的逆转、症状的改善、住院治疗的减少和死亡率的降低相关。 心力衰竭的慢性β受体阻滞剂治疗与收缩功能的增强、血流动力学的改善、病理重塑的逆转、症状的改善、住院治疗的减少和死亡率的降低相关。 β-受体阻滞剂治疗的长期益处的临床证据非常充分，因此现在推荐所有具有 II 级或 III 级心力衰竭症状且无特定禁忌症的患者接受该治疗。 本研究将调查长期卡维地洛治疗是否会产生对卡维地洛α1-肾上腺素受体阻断作用的耐受性。我们将测量 17 名心力衰竭受试者对去氧肾上腺素（一种纯 α1 激动剂）输注的血压和心率反应。这些测量将在卡维地洛治疗开始前、卡维地洛增量期间以及连续卡维地洛治疗 6 个月后进行。将测量收缩压增加 20 毫米汞柱 (PS20) 所需的去氧肾上腺素剂量和舒张压增加 20 毫米汞柱 (PD20) 所需的去氧肾上腺素剂量。将计算并比较这些剂量的剂量比。在入组之前，将获取血液样本以分析可能影响个体对去氧肾上腺素反应的α1-肾上腺素受体多态性。